Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 52 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIVCompletedNCT05330143Phase 2
• A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural EffusionStatus unknownNCT05330065Phase 1/2
• A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesCompletedNCT05329766Phase 2
• A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05329025Phase 2
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaWithdrawnNCT05327738Phase 2
• An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
• Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant LesionsActive, not recruitingNCT05327270Phase 1
• PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerStatus unknownNCT05325684Phase 1/2
• Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyStatus unknownNCT05322187Phase 2/3
• Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ LymphomaStatus unknownNCT05320081Phase 2
• SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerActive, not recruitingNCT05319574Phase 2
• A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2
• Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1
• Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric CancerStatus unknownNCT05311189Phase 2
• Tislelizumab and Radiotherapy for Recurrent Cervical CancerStatus unknownNCT05310383Phase 2
• Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05309629Phase 2
• Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid TumorsCompletedNCT05309187Phase 1
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingNCT05308446Phase 2
• Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedNCT05304546Phase 2
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsCompletedNCT05302921Phase 2
• Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Phase 2
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
• Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsActive, not recruitingNCT05300282Phase 1/2
• A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsCompletedNCT05298592Phase 1
• Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Phase 3
• Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic CancerStatus unknownNCT05298020Phase 2
• XmAb20717 in Advanced Biliary Tract CancersCompletedNCT05297903Phase 2
• Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2
• KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05294172Phase 3
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
• Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRCStatus unknownNCT05292417Phase 2
• Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal CarcinomaWithdrawnNCT05290194Phase 2
• Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)CompletedNCT05289856Phase 2
• Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaTerminatedNCT05289492Phase 1
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2
• Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingNCT05286801Phase 1/2
• Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2
• Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruitingNCT05286060Phase 2
• Sargramostim With Ipilimumab Containing Therapy in Patients With Solid TumorsWithdrawnNCT05284214Phase 2
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2
• FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
• ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsCompletedNCT05277402Phase 1
• First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
• Thiopurine Enhanced Mutations for PD-1/Ligand-1 EfficacyCompletedNCT05276284Phase 1/2
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
• Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruitingNCT05271318Phase 1/2
• Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella TrialStatus unknownNCT05270889Phase 2
• Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaCompletedNCT05268510Phase 2
• Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or ChemoradiotherapyStatus unknownNCT05267392Phase 1/2
• Atezolizumab Plus CArboplatin Plus Nab-paclitaxelActive, not recruitingNCT05266937Phase 2
• Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT05265962Phase 2
• ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without MetastasesTerminatedNCT05265013Phase 2
• Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
• Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II StudyStatus unknownNCT05262985Phase 2
• A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedNCT05262959Phase 2
• JS001+IMP4297 in Patients With Advanced CancerWithdrawnNCT05262842Phase 1
• NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1
• A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
• A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabActive, not recruitingNCT05259709Phase 1
• Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2
• A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedNCT05256472Phase 2
• Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)WithdrawnNCT05255666Phase 2
• A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)CompletedNCT05254899Phase 2
• Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Active, not recruitingNCT05253118Phase 2
• A Clinical Study of TAB006 in Patients With Previously Treated, Advanced MalignanciesWithdrawnNCT05253105Phase 1
• Docetaxel/Pembrolizumab in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05252429Phase 2
• Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT05251662Phase 2
• A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedNCT05249426Phase 1
• AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCActive, not recruitingNCT05247684Phase 2
• A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical CancerStatus unknownNCT05247619Phase 2
• A Phase I Study of IBI325 in Patients With Advanced Solid TumorStatus unknownNCT05246995Phase 1
• HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerStatus unknownNCT05246982Phase 2
• ChemoRadiation And Tislelizumab for Esophageal/EGJ CancerWithdrawnNCT05245760Phase 2
• AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT05244993Phase 2
• Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLCStatus unknownNCT05244837Phase 2
• Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLCActive, not recruitingNCT05244213Phase 2
• A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT05242445Phase 1
• Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder CancerActive, not recruitingNCT05241340Phase 2
• Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown PrimaryStatus unknownNCT05241132Phase 2
• Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent HepatocarcinomaStatus unknownNCT05240404Phase 2
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active, not recruitingNCT05239741Phase 3
• Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant TumorsCompletedNCT05235542Phase 1/2
• A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerActive, not recruitingNCT05235516Phase 3
• Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBCWithdrawnNCT05233696Phase 2
• Clinical Study of KD6001 in Advanced Solid TumoursCompletedNCT05230290Phase 1
• A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruitingNCT05229497Phase 1/2
• PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal CarcinomaStatus unknownNCT05229315Phase 2
• A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCActive, not recruitingNCT05228496Phase 2
• A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05227664Phase 2
• AK104 in Neoadjuvant Treatment of Cervical CancerCompletedNCT05227651Phase 2
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1
• An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalStatus unknownNCT05225844Phase 2
• Nivolumab for Recurrent/Metastatic CarcinosarcomaStatus unknownNCT05224999Phase 2

← Immune Checkpoint Inhibitors overview